Nyxoah Launches Search for U.S.-Based CEO to Lead Genio Rollout

The company says the move is meant to speed U.S. commercialization following FDA approval with early post‑approval launch activity.

Overview

The Nyxoah board formally began a search for a U.S.-based chief executive on Thursday to run the company from its largest strategic market and drive the next growth phase.
Incumbent CEO Olivier Taelman, who has led the company for seven years, will continue to run daily operations and to support onboarding of the future CEO during the transition.
Nyxoah framed the leadership change as a way to accelerate commercial traction for Genio in the United States after the device won FDA premarket approval and entered an early post‑approval launch.
The company highlights a regulatory and clinical foundation for the push, including CE marking in 2019, BETTER SLEEP CE expansion to CCC patients, positive DREAM IDE pivotal results, and FDA PMA approval for a defined adult OSA subgroup in August 2025.
A U.S.-based CEO could speed sales, clinician training, and payer engagement and may shift investor focus toward U.S. growth, but the company cautioned that execution and market risks disclosed in its filings remain.